A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial

Mette Bjørndal Axelsen; Iris Eshed; Kim Hørslev-Petersen; Kristian Stengaard-Pedersen; Merete Lund Hetland; Jakob Møller; Michael Peter Junker; Jan Pødenphanth; Annette Schlemmer; Torkell Juulsgaad Ellingsen; Palle Ahlquist; Hanne Lindegaard; Asta Linauskas; Mette Yde Dam; Ib Tønder Hansen; Hans Christian Horn; Christian Gytz Ammitzbøll; Anette Jerup Jørgensen; Sophine B Krintel; Johnny Raun; Niels Steen Krogh; Julia Sidenius Johansen; Mikkel Ostergaard; OPERA study group

doi:10.1136/annrheumdis-2013-204537

A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial

Mette Bjørndal Axelsen, Iris Eshed, Kim Hørslev-Petersen, Kristian Stengaard-Pedersen, Merete Lund Hetland, Jakob Møller, Michael Peter Junker, Jan Pødenphanth, Annette Schlemmer, Torkell Juulsgaad Ellingsen, Palle Ahlquist, Hanne Lindegaard, Asta Linauskas, Mette Yde Dam, Ib Tønder Hansen, Hans Christian Horn, Christian Gytz Ammitzbøll, Anette Jerup Jørgensen, Sophine B Krintel, Johnny RaunNiels Steen Krogh, Julia Sidenius Johansen, Mikkel Ostergaard, OPERA study group

63 Citationer (Scopus)

Abstract

To investigate whether a treat-to-target strategy with methotrexate and intra-articular glucocorticosteroid injections suppresses MRI inflammation and halts structural damage progression in patients with early rheumatoid arthritis (ERA), and whether adalimumab provides an additional effect.

Originalsprog	Engelsk
Tidsskrift	Annals of the Rheumatic Diseases
Vol/bind	74
Udgave nummer	5
Sider (fra-til)	867-75
ISSN	0003-4967
DOI	https://doi.org/10.1136/annrheumdis-2013-204537
Status	Udgivet - 2015

Adgang til dokumentet

10.1136/annrheumdis-2013-204537

Andre filer og links

Link to publication in Scopus

Fingeraftryk

Dyk ned i forskningsemnerne om 'A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Axelsen, M. B., Eshed, I., Hørslev-Petersen, K., Stengaard-Pedersen, K., Hetland, M. L., Møller, J., Junker, M. P., Pødenphanth, J., Schlemmer, A., Ellingsen, T. J., Ahlquist, P., Lindegaard, H., Linauskas, A., Dam, M. Y., Hansen, I. T., Horn, H. C., Ammitzbøll, C. G., Jørgensen, A. J., Krintel, S. B., ... OPERA study group (2015). A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. Annals of the Rheumatic Diseases, 74(5), 867-75. https://doi.org/10.1136/annrheumdis-2013-204537

A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. / Axelsen, Mette Bjørndal; Eshed, Iris; Hørslev-Petersen, Kim et al.
I: Annals of the Rheumatic Diseases, Bind 74, Nr. 5, 2015, s. 867-75.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Axelsen, MB, Eshed, I, Hørslev-Petersen, K, Stengaard-Pedersen, K, Hetland, ML , Møller, J, Junker, MP, Pødenphanth, J, Schlemmer, A, Ellingsen, TJ, Ahlquist, P, Lindegaard, H, Linauskas, A, Dam, MY, Hansen, IT, Horn, HC, Ammitzbøll, CG, Jørgensen, AJ, Krintel, SB, Raun, J, Krogh, NS, Johansen, JS , Ostergaard, M & OPERA study group 2015, 'A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial', Annals of the Rheumatic Diseases, bind 74, nr. 5, s. 867-75. https://doi.org/10.1136/annrheumdis-2013-204537

Axelsen MB, Eshed I, Hørslev-Petersen K, Stengaard-Pedersen K, Hetland ML , Møller J et al. A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial. Annals of the Rheumatic Diseases. 2015;74(5):867-75. doi: 10.1136/annrheumdis-2013-204537

Axelsen, Mette Bjørndal ; Eshed, Iris ; Hørslev-Petersen, Kim et al. / A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis : results from the OPERA randomised controlled trial. I: Annals of the Rheumatic Diseases. 2015 ; Bind 74, Nr. 5. s. 867-75.

@article{ef92023174074fa79965053cb9b2019d,

title = "A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial",

abstract = "To investigate whether a treat-to-target strategy with methotrexate and intra-articular glucocorticosteroid injections suppresses MRI inflammation and halts structural damage progression in patients with early rheumatoid arthritis (ERA), and whether adalimumab provides an additional effect.",

author = "Axelsen, \{Mette Bj{\o}rndal\} and Iris Eshed and Kim H{\o}rslev-Petersen and Kristian Stengaard-Pedersen and Hetland, \{Merete Lund\} and Jakob M{\o}ller and Junker, \{Michael Peter\} and Jan P{\o}denphanth and Annette Schlemmer and Ellingsen, \{Torkell Juulsgaad\} and Palle Ahlquist and Hanne Lindegaard and Asta Linauskas and Dam, \{Mette Yde\} and Hansen, \{Ib T{\o}nder\} and Horn, \{Hans Christian\} and Ammitzb{\o}ll, \{Christian Gytz\} and J{\o}rgensen, \{Anette Jerup\} and Krintel, \{Sophine B\} and Johnny Raun and Krogh, \{Niels Steen\} and Johansen, \{Julia Sidenius\} and Mikkel Ostergaard and \{OPERA study group\}",

note = "COPECARE",

year = "2015",

doi = "10.1136/annrheumdis-2013-204537",

language = "English",

volume = "74",

pages = "867--75",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "Elsevier BV",

number = "5",

}

TY - JOUR

T1 - A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis

T2 - results from the OPERA randomised controlled trial

AU - Axelsen, Mette Bjørndal

AU - Eshed, Iris

AU - Hørslev-Petersen, Kim

AU - Stengaard-Pedersen, Kristian

AU - Hetland, Merete Lund

AU - Møller, Jakob

AU - Junker, Michael Peter

AU - Pødenphanth, Jan

AU - Schlemmer, Annette

AU - Ellingsen, Torkell Juulsgaad

AU - Ahlquist, Palle

AU - Lindegaard, Hanne

AU - Linauskas, Asta

AU - Dam, Mette Yde

AU - Hansen, Ib Tønder

AU - Horn, Hans Christian

AU - Ammitzbøll, Christian Gytz

AU - Jørgensen, Anette Jerup

AU - Krintel, Sophine B

AU - Raun, Johnny

AU - Krogh, Niels Steen

AU - Johansen, Julia Sidenius

AU - Ostergaard, Mikkel

AU - OPERA study group

N1 - COPECARE

PY - 2015

Y1 - 2015

N2 - To investigate whether a treat-to-target strategy with methotrexate and intra-articular glucocorticosteroid injections suppresses MRI inflammation and halts structural damage progression in patients with early rheumatoid arthritis (ERA), and whether adalimumab provides an additional effect.

AB - To investigate whether a treat-to-target strategy with methotrexate and intra-articular glucocorticosteroid injections suppresses MRI inflammation and halts structural damage progression in patients with early rheumatoid arthritis (ERA), and whether adalimumab provides an additional effect.

UR - https://www.scopus.com/pages/publications/84926677953

U2 - 10.1136/annrheumdis-2013-204537

DO - 10.1136/annrheumdis-2013-204537

M3 - Journal article

C2 - 24412895

SN - 0003-4967

VL - 74

SP - 867

EP - 875

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 5

ER -